
Purpose of program The Transplant Ambassador Program (TAP) is a patient-led, volunteer-driven support program that connects patients with kidney failure and potential living kidney donors to kidney transplant recipients and living kidney donors. TAP was developed to address a peer support gap identified by patients, by providing emotional support, practical guidance, and one-on-one conversations. Sources of information Lived experience of patients with kidney failure (e.g., kidney transplant recipients) and living kidney donors, information from existing peer support programs, input from individuals working in advanced chronic kidney disease (CKD) and dialysis clinics (e.g., nephrologists and nurses), and input from provincial transplant and kidney care organizations. Methods TAP was developed primarily by patients (i.e., kidney transplant recipients and living kidney donors), in partnership with researchers and kidney health care professionals. Transplant ambassador volunteers lead and run the program, including developing and delivering training to transplant ambassadors. Implementation of TAP began in November 2017 at half of the 27 CKD programs in Ontario, Canada, as part of a multicomponent cluster-randomized clinical trial. Key findings TAP has been operating for over eight years, expanding to all of Ontario’s CKD programs and to Atlantic Canada, with over 200 active transplant ambassadors. Since its launch, TAP has logged over 10,000 conversations with patients and potential donors and facilitated 25 educational webinars on kidney transplantation. Limitations Most patient referrals to TAP are initiated by healthcare professionals, who connect patients to the program. In some hospitals, low referral rates have resulted in transplant ambassadors stepping away due to a lack of work. Implications TAP demonstrates that patients can scale a volunteer-run, peer support model provincially and nationally. Patient volunteers have led this program and embedded it into kidney care, with support from provincial organizations, reaching many patients with CKD and potential living kidney donors.
Purpose Glomerulonephritis (GN) comprises a heterogeneous group of immune-mediated kidney diseases and is the third leading cause of kidney failure. Although increasing clinical trials in this area have led to new therapeutic options, selecting the right treatment for the right patient remains challenging. We review current precision medicine initiatives that integrate deep clinical phenotyping with genomics and multi-omics approaches to identify pathway-specific therapies and refine risk stratification. We also discuss how these strategies may reshape clinical trial design and treatment selection in GN. Sources of Information Literature was identified through PubMed and Google Scholar from inception to 2026. Patient perspectives were informed by engagement with patient partners. Methods Search terms included “precision medicine”, “nephrology”, and “glomerulonephritis”. Key Findings Advances in genetics, multi-omics profiling, and large collaborative cohorts have revealed molecularly distinct subtypes within GN, enabling biomarker-guided diagnosis, improved risk stratification, and targeted therapy. Initiatives such as the Kidney Precision Medicine Project and the Nephrotic Syndrome Study Network (NEPTUNE) integrate kidney tissue, blood, urine, and clinical data to identify actionable biological pathways. The NEPTUNE Match initiative aims to align patients with clinical trials most likely to benefit them based on their molecular profiles. Disease-specific examples, including PLA2R antibody monitoring in membranous nephropathy and proof-of-concept studies in focal segmental glomerulosclerosis, highlight the potential of precision medicine approaches that can translate into clinical care. Genetic variation at the human leukocyte antigen (HLA) locus may represent a shared risk factor across GN subtypes. Incorporating sex- and gender-based analyses into precision frameworks will be essential to ensure appropriate risk stratification and therapeutic selection. Importantly, patient-centered initiatives demonstrate high levels of engagement and willingness to participate in precision medicine research. Collectively, these findings support a paradigm shift toward personalized GN management. Limitations A systematic review was not conducted, and our search was restricted to English-language articles.
Background Ontario recently designated Black people aged 40 and older as a high-risk group for annual chronic kidney disease (CKD) screening in primary care, yet population-level data have been limited. Objective To describe and compare kidney failure incidence, prevalence, pre-dialysis care, treatment modality, and mortality between Black and White individuals in Ontario. Design Population-based descriptive analysis of provincial administrative health data, 2017–2024. Setting All adult kidney programs in Ontario, Canada, captured in the Ontario Renal Reporting System. Patients and Measurements All individuals receiving maintenance dialysis were included. Age-standardized rates of dialysis initiation, prevalence, and mortality were compared between Black and White individuals. Time from first meeting advanced CKD care lab criteria (eGFR <15 mL/min/1.73 m 2 or 2-year kidney failure risk ≥10%) to dialysis initiation and home dialysis uptake were compared. Results Among 26,042 incident dialysis patients, 1,674 (6.4%) were Black and 15,888 (61.0%) White. Black individuals were younger at initiation (median 62.0 vs. 69.9 years) with lower eGFR (6.7 vs. 8.3 mL/min/1.73 m 2 ). In 2024, age-standardized incidence of dialysis initiation among Black individuals was 1.8-fold higher (292.1 vs. 162.4 per million) and prevalence was 3.5-fold higher. Among those meeting advanced CKD care lab criteria, Black individuals had a shorter median interval to dialysis (593 vs. 666 days) and lower home dialysis uptake (18.8% vs. 24.1%). Age-standardized mortality was lower. Limitations Self-reported racialized identity was ascertained from administrative data and has not been formally validated, with a rising proportion recorded as “unknown” (19.6% by 2024); mortality and modality comparisons were standardized for age but not comorbidity; kidney transplantation was not assessed; and all analyses were restricted to individuals who reached maintenance dialysis. Conclusions Black individuals in Ontario experience higher kidney failure rates, begin dialysis younger with more advanced disease, and progress more rapidly from advanced CKD care to dialysis. These findings support Ontario’s recent recommendation of annual CKD screening for Black individuals aged 40 and older in primary care and underscore the need for earlier detection and intervention.
Purpose of review Chronic kidney disease (CKD) represents a progressive and severe medical condition that imposes a substantial economic burden. This systematic review aimed to summarize the available evidence regarding the costs and cost-utility of SGLT2 inhibitors in managing CKD. Sources of information A systematic literature search was conducted from inception to November 07, 2025, using MEDLINE, EMBASE, and Scopus databases. Methods Titles and abstracts were screened, followed by an eligibility assessment of full texts. The quality of the studies was evaluated using the Quality of Health Economic Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. Cost-utility results were synthesized narratively. Key findings Thirteen cost-utility studies met the inclusion criteria, evaluating Dapagliflozin, Empagliflozin, and Canagliflozin. The addition of Empagliflozin or Dapagliflozin to standard care (SoC) was cost-effective compared with SoC alone in patients with chronic kidney disease (CKD), regardless of type 2 diabetes (T2D) status. Among CKD patients with T2D, SGLT2 inhibitors combined with SoC were cost-saving in high-income countries from a health system perspective; however, Dapagliflozin was not cost-effective when compared to Canagliflozin. No study fulfilled all criteria of the QHES and CHEERS checklists. Limitations This systematic review has several limitations, including restriction to English-language studies, potential subjectivity in methodological and reporting quality assessments, and possible publication bias. In addition, heterogeneity in study settings, interventions, and service utilization limits direct comparisons across studies, although the findings provide valuable insights into the cost-utility of SGLT2 inhibitors for CKD management.
Background The purine nucleoside adenosine has established anti-inflammatory effects whilst also being reported to promote organ fibrosis by signaling through the adenosine A2a and A2b receptors. Objective Here, we examined the consequences of deletion of the adenosine A2b receptor from fibroblasts in mice with obstructive uropathy caused by unilateral ureteral obstruction (UUO). Methods Experiments were performed in C57BL/6N mice after UUO, and in mouse embryonic fibroblasts (MEFs) stimulated with recombinant transforming growth factor-β1 (TGF-β1). Tamoxifen-inducible fibroblast-specific adenosine A2b receptor knockout mice (A2B FibKO ) were generated by breeding Adora2b fl/fl mice with Col1a2 CreER + mice, and these mice were compared with Adora2b fl/fl mice (A2B Ctrl ) 14 days after sham or UUO surgery. Results mRNA levels of Adora2b , the gene that encodes the adenosine A2b receptor, were increased in mice with UUO, and knockdown of Adora2b diminished fibrotic gene upregulation in MEFs. In A2B FibKO mice with UUO, fibroblast-specific adenosine A2b receptor knockout diminished upregulation of mRNA levels of fibrotic genes but increased mRNA indices of kidney inflammation and tubule injury. These gene expression changes were reflected in a numerical but non-significant reduction in interstitial fibrosis, with persistent tubule epithelial programmed cell death and macrophage accumulation. Expression of Adora2a remained expectedly elevated in UUO kidneys. Conclusions The findings illustrate the bidirectional effects of the adenosine A2b receptor in kidney fibrosis and inflammation, and the relatively small consequences of its cell-specific gene deletion, at least in UUO mice. Specific targeting of adenosine receptors to improve outcomes for kidney disease represents a therapeutic challenge.